Exenatide	Insulin glargine	Cost-effectiveness	1948	2191	the cost-effectiveness ratio of exenatide vs. insulin glargine at the current UK NHS price was -Â£29,149/QALY (insulin glargine dominant) and thus exenatide is not cost-effective when compared with insulin glargine, at the current UK NHS price.
Exenatide	Insulin glargine	Severe hypoglycaemic events	33881	34130	Although there were fewer nocturnal hypoglycaemic events associated with exenatide, their contribution to improving quality of life was offset by higher daytime events and overall higher severe hypoglycaemic events when compared to insulin glargine.
